Ph.D., CSO, Trovagene
Mark Erlander has more than 18 years of experience directing and leading research and development for gene discovery, with a strong focus on molecular diagnostics. Since 2012, Dr. Erlander has also served as Chief Scientific Officer of Gensignia, Inc., a lung cancer diagnostics company. Prior to joining Trovagene, Dr. Erlander was chief scientific officer at bioTheranostics, a bioMerieux company. Previously, Dr. Erlander was a group leader and subsequently a research fellow at the R.W. Johnson Pharmaceutical Research Institute (Johnson & Johnson). He was also an assistant member and postdoctoral fellow at The Scripps Research Institute in the Department of Molecular Biology. Dr. Erlander holds a BS degree in Biochemistry from the University of California, Davis; an MS degree in Biochemistry from Iowa State University; and a Ph.D. in Neuroscience from the University of California, Los Angeles.
Revolutionizing Cancer Care with Urine ctDNA
Genomically driven cancer therapy holds great potential. However, precision oncology is not without its criticisms, including, invasiveness of repeated biopsies needed for identification of genomic markers, tumor heterogeneity, evolution of “new” driver mutations, paucity of genomically driven therapies and clinical trials, and emergence of resistance mutations. This “snapshot in time” approach to characterizing tumors has proven to be problematic. Here we discuss the combination of detecting and monitoring circulating tumor DNA (ctDNA) with a truly non-invasive approach using urine sampling for precision cancer monitoring. This approach can uniquely address these gaps in cancer care, in a manner, that encourages engagement of the most important component of precision oncology; the patient.